178 related articles for article (PubMed ID: 24986094)
1. Glycopyrronium does not affect QT interval in healthy subjects: a randomized, three- period, cross-over, placebo- and positive-controlled study.
Drollmann A; Sechaud R; Pal P; Hara H; Uziel-Fusi S; Winkle P
Int J Clin Pharmacol Ther; 2014 Sep; 52(9):739-45. PubMed ID: 24986094
[TBL] [Abstract][Full Text] [Related]
2. Effect of dual bronchodilation with QVA149 on cardiac safety in healthy volunteers.
Drollmann A; Brown M; Sechaud R; Perry S; Hara H; Jones I; Febbraro S
Int J Clin Pharmacol Ther; 2014 May; 52(5):369-80. PubMed ID: 24569129
[TBL] [Abstract][Full Text] [Related]
3. A randomized, placebo- and moxifloxacin-controlled thorough QT study of umeclidinium monotherapy and umeclidinium/vilanterol combination in healthy subjects.
Kelleher D; Tombs L; Preece A; Brealey N; Mehta R
Pulm Pharmacol Ther; 2014 Oct; 29(1):49-57. PubMed ID: 25020273
[TBL] [Abstract][Full Text] [Related]
4. Effect of levetiracetam on cardiac repolarization in healthy subjects: a single-dose, randomized, placebo- and active-controlled, four-way crossover study.
Hulhoven R; Rosillon D; Bridson WE; Meeus MA; Salas E; Stockis A
Clin Ther; 2008 Feb; 30(2):260-70. PubMed ID: 18343264
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the effect of Naloxegol on cardiac repolarization: a randomized, placebo- and positive-controlled crossover thorough QT/QTc study in healthy volunteers.
Gottfridsson C; Carlson G; Lappalainen J; Sostek M
Clin Ther; 2013 Dec; 35(12):1876-83. PubMed ID: 24238792
[TBL] [Abstract][Full Text] [Related]
6. A case report of QT prolongation with glycopyrronium bromide in a patient with chronic tamoxifen use.
Chiu MH; Al-Majed NS; Stubbins R; Pollmann D; Sandhu RK
BMC Res Notes; 2016 Jun; 9():310. PubMed ID: 27301406
[TBL] [Abstract][Full Text] [Related]
7. Thorough QT study of the effects of vildagliptin, a dipeptidyl peptidase IV inhibitor, on cardiac repolarization and conduction in healthy volunteers.
He YL; Zhang Y; Serra D; Wang Y; Ligueros-Saylan M; Dole WP
Curr Med Res Opin; 2011 Jul; 27(7):1453-63. PubMed ID: 21609207
[TBL] [Abstract][Full Text] [Related]
8. Aclidinium bromide, a long-acting antimuscarinic, does not affect QT interval in healthy subjects.
Lasseter KC; Aubets J; Chuecos F; Gil EG
J Clin Pharmacol; 2011 Jun; 51(6):923-32. PubMed ID: 20959525
[TBL] [Abstract][Full Text] [Related]
9. Safety of inhaled glycopyrronium in patients with COPD: a comprehensive analysis of clinical studies and post-marketing data.
D'Urzo AD; Kerwin EM; Chapman KR; Decramer M; DiGiovanni R; D'Andrea P; Hu H; Goyal P; Altman P
Int J Chron Obstruct Pulmon Dis; 2015; 10():1599-612. PubMed ID: 26316734
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular safety of QVA149, a combination of Indacaterol and NVA237, in COPD patients.
Van de Maele B; Fabbri LM; Martin C; Horton R; Dolker M; Overend T
COPD; 2010 Dec; 7(6):418-27. PubMed ID: 21166630
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the effects of bitopertin (RG1678) on cardiac repolarization: a thorough corrected QT study in healthy male volunteers.
Hofmann C; Banken L; Hahn M; Swearingen D; Nagel S; Martin-Facklam M
Clin Ther; 2012 Oct; 34(10):2061-71. PubMed ID: 22980315
[TBL] [Abstract][Full Text] [Related]
12. Cardiac repolarization with Gabapentin enacarbil in a randomized, double-blind, placebo- and active-controlled, crossover thorough QT/QTc study in healthy adults.
Davy M; Upward J; Arumugham T; Twomey C; Chen C; Stier B
Clin Ther; 2013 Dec; 35(12):1964-74. PubMed ID: 24290737
[TBL] [Abstract][Full Text] [Related]
13. Loxapine delivered as a thermally generated aerosol does not prolong QTc in a thorough QT/QTc study in healthy subjects.
Spyker DA; Voloshko P; Heyman ER; Cassella JV
J Clin Pharmacol; 2014 Jun; 54(6):665-74. PubMed ID: 24375070
[TBL] [Abstract][Full Text] [Related]
14. Once-daily glycopyrronium via the Breezhaler® device for the treatment of COPD: pharmacological and clinical profile.
Molimard M; D'Andrea P
Expert Rev Clin Pharmacol; 2013 Sep; 6(5):503-17. PubMed ID: 23971870
[TBL] [Abstract][Full Text] [Related]
15. Revefenacin, a Long-Acting Muscarinic Antagonist, Does Not Prolong QT Interval in Healthy Subjects: Results of a Placebo- and Positive-Controlled Thorough QT Study.
Borin MT; Barnes CN; Darpo B; Pendyala S; Xue H; Bourdet DL
Clin Pharmacol Drug Dev; 2020 Jan; 9(1):130-139. PubMed ID: 31468714
[TBL] [Abstract][Full Text] [Related]
16. Effect of nalmefene 20 and 80 mg on the corrected QT interval and T-wave morphology: a randomized, double-blind, parallel-group, placebo- and moxifloxacin-controlled, single-centre study.
Matz J; Graff C; Vainio PJ; Kallio A; Højer AM; Struijk JJ; Kanters JK; Andersen MP; Toft E
Clin Drug Investig; 2011 Nov; 31(11):799-811. PubMed ID: 21967071
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of Glycopyrronium Following Repeated Once-Daily Inhalation in Healthy Chinese Subjects.
Sechaud R; Machineni S; Tillmann HC; Hara H; Tan X; Zhao R; Ren S; Hou J
Eur J Drug Metab Pharmacokinet; 2016 Dec; 41(6):723-731. PubMed ID: 26428357
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and safety of a single dose of the novel LAMA/LABA fixed-dose combination of glycopyrronium/formoterol fumarate dihydrate metered dose inhaler, formulated using co-suspension delivery technology, in Japanese healthy subjects.
Reisner C; Miller J; DePetrillo P; Maes A; Siddiqui S; Martin UJ
Pulm Pharmacol Ther; 2018 Dec; 53():33-38. PubMed ID: 30218695
[TBL] [Abstract][Full Text] [Related]
19. Effects of a supratherapeutic dose of investigational orally inhaled dihydroergotamine (MAP0004) on QT interval: a randomized, double-blind, active- and placebo-controlled crossover study in healthy volunteers.
Kori S; Kellerman DJ; Voloshko P; Haugen G
Clin Ther; 2012 Sep; 34(9):1920-8. PubMed ID: 22917853
[TBL] [Abstract][Full Text] [Related]
20. Comparing the cardiovascular therapeutic indices of glycopyrronium and tiotropium in an integrated rat pharmacokinetic, pharmacodynamic and safety model.
Trifilieff A; Ethell BT; Sykes DA; Watson KJ; Collingwood S; Charlton SJ; Kent TC
Toxicol Appl Pharmacol; 2015 Aug; 287(1):9-16. PubMed ID: 26026369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]